Management of autonomic dysfunction in patients with hereditary transthyretin amyloidosis is feasible and can result in improved quality of life.
Does management of autonomic dysfunction improve quality of life in patients with hereditary transthyretin amyloidosis (hATTR)?
Management of autonomic dysfunction in hATTR amyloidosis is feasible and improves patient quality of life, though the specific impact of novel disease-modifying therapies requires further study.
PURPOSE: Hereditary transthyretin amyloidosis (hATTR) is a severe adult-onset progressive disease mainly involving the peripheral nervous system and the heart, with a prominent impact on the autonomic nervous system. This review summarizes the clinical aspects of autonomic dysfunction in hATTR, and their impact on quality of life as well as potential therapeutic options. METHODS: Literature review. RESULTS: Autonomic dysfunction, causing neurogenic orthostatic hypotension, gastroparesis, constipation, diarrhea, bladder dysfunction, and erectile dysfunction in males, has a major impact on the quality of life of patients with hATTR. Improvement of qualify of life in patients with hATTR implies periodic symptomatic screening and early management, taking into consideration comorbidities and medication side effects. The specific effect of the disease-modifying treatment on this aspect remains to be unraveled. CONCLUSIONS: Management of autonomic dysfunction in patients with hAATR is feasible and can result in improved qualify of life. Novel disease-modifying treatments for hAATR may contribute to improve autonomic dysfunction, although specific studies are required.
Gendre et al. (Sun,) conducted a review in Hereditary transthyretin amyloidosis (hATTR) with autonomic neuropathy. Management of autonomic dysfunction was evaluated. Management of autonomic dysfunction in patients with hereditary transthyretin amyloidosis is feasible and can result in improved quality of life.